Sankyo licenses KAI's PKC inhibitor CV drug
Sankyo, a wholly-owned subsidiary of Janapese drug major Daiichi Sankyo, has signed a global development accord with the USA's KAI Pharmaceuticals for the latter's heart disease drug candidate KAI-9803.
The agent and its related compounds are novel delta protein kinase C inhibitors which are expected to prevent myocardial tissue deaths and congestive heart failure in patients with acute myocardial infarction under revascularization.
KAI-9803 is a first-in-class agent for this indication and is currently in a Phase I/II safety and efficacy trial in patients with acute MI on reperfusion via balloon angioplasty. KAI noted that the US Food and Drug Administration has granted the drug fast track status.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze